Oragenics, Inc. Submits Investigator’s Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury (mTBI)

This upcoming Phase II study aims to establish the feasibility of acute intranasal administration in mTBI patients and generate initial proof-of-concept data through cognitive testing, visual motor testing, and biomarker analysis.

Despite the high incidence of concussions, no FDA-approved drug therapies currently exist, leaving a significant unmet medical need.

https://ir.oragenics.com/press-releases/detail/205